Biogen (BMY) Q4 Results Exceed Estimates, Hopes FY26 Adj. EPS Above Outlook

Biogen (BMY) reported fourth-quarter revenue of $3.28 billion, up 13% year-over-year, surpassing estimates of $3.20 billion. Adjusted EPS for the quarter was $1.43, exceeding the average analyst forecast of $1.39. The company attributed the strong performance to higher sales of its Alzheimer’s drug Aduhelm and improved pricing. For 2026, Biogen guided to adjusted EPS of $3.50 per share, above the average estimate of $3.45, reflecting positive guidance across key therapeutic areas and a favorable pricing environment.